nach oben

Digestive Diseases and Sciences

Erschienen in:

01.07.2012 | Case Report

Jaundice Due to Suspected Statin Hepatotoxicity: A Case Series

verfasst von: Ottar M. Bergmann, Gudjon Kristjansson, Jon G. Jonasson, Einar S. Björnsson

Erschienen in: Digestive Diseases and Sciences | Ausgabe 7/2012

Einloggen, um Zugang zu erhalten

Abstract

Statin drugs are widely used worldwide and are generally considered safe and well tolerated. Only small proportion of patients receiving statins develop elevations of liver enzymes and an even smaller proportion will have clinically significant hepatitis induced by statins. We describe four patients with jaundice caused by drug-induced liver injury, where the most likely agent was a statin drug, over a period of approximately three year in Iceland. We calculate the risk of jaundice caused by statin drugs, from sale in the whole country of Iceland, to be one in 17,434 users a year. This is a higher risk than has previously been estimated and we challenge the current opinion that statins rarely cause clinically significant drug-induced liver injury and encourage alertness when managing patients with statins with regard to clinical signs of hepatitis before jaundice occurs.

Bradford RH, Shear CL, Chremos AN, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med. 1999;151:43–49.CrossRef

Wright RA, Flapan AD, McMurray J, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin survival study (4S). Lancet. 1994;344:1383–1389.

Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711–1718.PubMedCrossRef

Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301–1307.PubMedCrossRef

Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. Rev Semin Liver Dis. 2009;29:412–422.CrossRef

Abraldes JG, Albillos A, Bañares R, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology. 2009;136:1651–1658.PubMedCrossRef

El-Serag HB, Johnson ML, Hachem C, Morgana RO. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology. 2009;136:1601–1608.PubMedCrossRef

Rallidis LS, Drakoulis CK, Parasi AS. Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis. 2004;174:193–196.PubMedCrossRef

Hyogo H, Tazuma S, Arihiro K, et al. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism. 2008;57:1711–1718.PubMedCrossRef

10.

Ekstedt M, Franzén LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol. 2007;47:135–141.PubMedCrossRef

11.

Tokunaga T, Ikegami T, Yoshizumi T, et al. Beneficial effects of fluvastatin on liver microcirculation and regeneration after massive hepatectomy in rats. Dig Dis Sci. 2008;53:2989–2994.PubMedCrossRef

12.

Bader T. The myth of statin-induced hepatotoxicity. Am J Gastroenterol. 2010;105:978–980.PubMedCrossRef

13.

Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. National Lipid Association Statin Safety Task Force Liver Expert Panel. Am J Cardiol. 2006;97:77C–81C.PubMedCrossRef

14.

Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46:1323–1330.PubMedCrossRef

15.

Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs-II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol. 1993;46:1331–1336.PubMedCrossRef

16.

Clarke AT, Mills PR. Atorvastatin associated liver disease. Dig Liver Dis. 2006;38:772–777.PubMedCrossRef

17.

Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol 2011; Epub. 08/31/2011.

18.

Weismantel D, Danis P. Clinical inquiries. What laboratory monitoring is appropriate to detect adverse drug reactions in patients on cholesterol-lowering agents? J Fam Pract. 2001;50:927–928.PubMed

19.

Andrade RJ, Lucena MI, Fernández MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Spanish Group for the Study of Drug-Induced Liver Disease. Gastroenterology. 2005;129:512–521.PubMed

20.

Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005;42:481–489.PubMedCrossRef

21.

Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Drug induced liver injury network (DILIN). Gastroenterology. 2008;135:1924–1934.PubMedCrossRef

22.

Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl. 2004;10:1018–1023.PubMedCrossRef

23.

Reuben A, Koch DG, Lee WM. Drug-induced acute liver failure:r of a US multicenter, prospective Study. Hepatology. 2010;52:2065–2076.PubMedCrossRef

24.

Perger L, Kohler M, Fattinger K, Flury R, Meier PJ, Pauli-Magnus C. Fatal liver failure with atorvastatin. J Hepatol. 2003;39:1095–1097.PubMedCrossRef

25.

Björnsson E, Jerlstad P, Bergqvist A, Olsson R. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scand J Gastroenterol. 2005;40:1095–1101.PubMedCrossRef

26.

Davern TJ, Chalasani N. Drug-induced liver injury in clinical trials: as rare as hens’ teeth. Am J Gastroenterol. 2009;104:1159–1161.PubMedCrossRef

27.

Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, Chalasani N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology. 2008;47:2003–2009.PubMedCrossRef

28.

Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004;126:1287–1292.PubMedCrossRef

29.

Schattner A, Kozak N, Friedman J. Captopril-induced jaundice: report of 2 cases and a review of 13 additional reports in the literature. Review. Am J Med Sci. 2001;322:236–240.PubMedCrossRef

30.

Kleiner DE. The pathology of drug-induced liver injury. Semin Liver Dis. 2009;29:364–372.PubMedCrossRef

31.

Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis. 2002;22:145–155.PubMedCrossRef

Titel: Jaundice Due to Suspected Statin Hepatotoxicity: A Case Series
verfasst von: Ottar M. Bergmann
Gudjon Kristjansson
Jon G. Jonasson
Einar S. Björnsson
Publikationsdatum: 01.07.2012
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 7/2012
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-011-1950-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2012

Quality of Polyp Resection During Colonoscopy: Are We Achieving Polyp Clearance?

Digestive Diseases and Sciences: Sadness, Satisfaction, and Sanguinity

Curcumin Ameliorates Hydrogen Peroxide-Induced Epithelial Barrier Disruption by Upregulating Heme Oxygenase-1 Expression in Human Intestinal Epithelial Cells

Wing Stents Versus Conventional Plastic Stents in the Biliary Tree: Imagination in Plastic Biliary Stent Designs Continues to Evolve

MUTYH Associated Polyposis Coli: One Common and One Rare Mutation